Catalyst Wire Dossier Catalyst Wire Dossier
FDA approval · 2022-09-08

FDA Approved: LIVTENCITY — Supplemental Application (Takeda Pharmaceuticals America, Inc.)

View source ↗

Summary

The FDA approved a supplemental application for LIVTENCITY (maribavir) filed by Takeda Pharmaceuticals America, Inc., indicating an approved update to its label…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • LIVTENCITY (MARIBAVIR)

Snippet

SUPPL AP for LIVTENCITY (MARIBAVIR)